Edgestream Partners, L.P. Acadia Pharmaceuticals Inc Transaction History
Edgestream Partners, L.P.
- $2.88 Billion
- Q1 2025
A detailed history of Edgestream Partners, L.P. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Edgestream Partners, L.P. holds 159,108 shares of ACAD stock, worth $3.4 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
159,108
Previous 264,390
39.82%
Holding current value
$3.4 Million
Previous $4.85 Million
45.54%
% of portfolio
0.09%
Previous 0.21%
Shares
8 transactions
Others Institutions Holding ACAD
# of Institutions
351Shares Held
165MCall Options Held
1.77MPut Options Held
307K-
Baker Bros. Advisors LP New York, NY42.9MShares$915 Million8.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.2MShares$324 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$257 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY8.54MShares$182 Million2.32% of portfolio
-
State Street Corp Boston, MA6.99MShares$149 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.45B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...